CAESAREA, Israel, Nov. 20,
2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer minimally-invasive
cryoablation technology that destroys tumors by freezing as an
alternative to surgical tumor removal, announced today that it will
issue a press release with its financial and operational results as
of and for the nine months ended September
30, 2024 before the Nasdaq Stock Market opens on
Tuesday, November 26, 2024. The
Company will also discuss such results and other corporate
developments on a conference call at 10:00
a.m. EST on the same day.
Conference call & webcast info:
Tuesday, November 26, 2024, at
10:00 am EST
US: 1-888-407-2553
Israel/International:
+972-3-918-0696
A live webcast will be available at:
https://Veidan.activetrail.biz/IcecureQ3-2024
A recording of the webcast will be available at:
ir.icecure-medical.com/
About IceCure Medical
IceCure Medical (Nasdaq: ICCM)
develops and markets advanced liquid-nitrogen-based cryoablation
therapy systems for the treatment of tumors (benign and cancerous)
by freezing, with the primary focus areas being breast, kidney,
bone and lung cancer. Its minimally invasive technology is a safe
and effective alternative to hospital surgical tumor removal that
is easily performed in a relatively short procedure. The Company's
flagship ProSense® system is marketed and sold worldwide for the
indications cleared and approved to date including in the U.S.,
Europe, and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses its
expected announcement of financial and operational results as of
and for the nine months ended September 30,
2024 and hosting a conference call related to such results.
Historical results of scientific research and clinical and
preclinical trials do not guarantee that the conclusions of future
research or trials will suggest identical or even similar
conclusions. Important factors that could cause actual results,
developments and business decisions to differ materially from those
anticipated in these forward-looking statements include, among
others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2023 filed with the U.S.
Securities and Exchange Commission (the "SEC") on April 3, 2024, and other documents filed with or
furnished to the SEC which are available on the SEC's website,
www.sec.gov. The Company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/4496307/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-third-quarter-2024-financial--operational-results-on-november-26-2024-302311232.html
SOURCE IceCure Medical
